U.S. Patent Granted for 4SC’s Oral HDAC Inhibitor Resminostat (4SC-201)
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, has announced that the U.S. Patent and Trademark Office has granted patent 7842820 for resminostat (4SC-201), an oral histone deacetylase (HDAC) inhibitor. This molecule is currently being developed in two Phase II trials in hepatocellular carcinoma and Hodgkin’s lymphoma.
The patent, entitled “novel sulfonylpyrroles”, covers the composition of matter and pharmaceutical compositions of a novel group of compounds, including resminostat, which inhibit HDACs. Resminostat is an oral HDAC inhibitor that targets a spectrum of HDAC isoenzymes. HDAC inhibitors modify the DNA arrangement of tumor cells to cause their differentiation and programmed cell death (apoptosis). This mechanism of action is considered to offer the particular potential to halt tumor progression and induce tumor regression in various cancers.
Dr Bernd Hentsch, Chief Development Officer at 4SC, commented: “We are pleased to have received this patent for our lead oncology compound resminostat, which is the first of two HDAC inhibitors in our pipeline. The current Phase II trials in hepatocellular cancer and Hodgkin’s lymphoma are progressing well and we look forward to commencing a Phase I/II trial in K-rasmutant colorectal cancer patients later this year. This patent underpins the commercial potential of resminostat, which we are broadly assessing through the selection of three cancer indications with different treatment paradigms, evaluating resminostat in monotherapy trials as well as in combination treatment approaches.”
The patent, entitled “novel sulfonylpyrroles”, covers the composition of matter and pharmaceutical compositions of a novel group of compounds, including resminostat, which inhibit HDACs. Resminostat is an oral HDAC inhibitor that targets a spectrum of HDAC isoenzymes. HDAC inhibitors modify the DNA arrangement of tumor cells to cause their differentiation and programmed cell death (apoptosis). This mechanism of action is considered to offer the particular potential to halt tumor progression and induce tumor regression in various cancers.
Dr Bernd Hentsch, Chief Development Officer at 4SC, commented: “We are pleased to have received this patent for our lead oncology compound resminostat, which is the first of two HDAC inhibitors in our pipeline. The current Phase II trials in hepatocellular cancer and Hodgkin’s lymphoma are progressing well and we look forward to commencing a Phase I/II trial in K-rasmutant colorectal cancer patients later this year. This patent underpins the commercial potential of resminostat, which we are broadly assessing through the selection of three cancer indications with different treatment paradigms, evaluating resminostat in monotherapy trials as well as in combination treatment approaches.”
